Pfizer stock at EUR 26.66, up 1.48% premarket
Published on 11/12/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer Develops Obesity Pipeline
- Pfizer is advancing berobenatide as an investigational monthly obesity treatment.
- Blackstone Life Sciences may provide up to USD 1.5 billion through 2028 under the strategic funding agreement.
- Pfizer retains control of clinical development and commercialization, while clinical results and regulatory approval remain key milestones.
Pfizer stock traded at EUR 26.66 on Lang & Schwarz at 08:31 CET on Thursday, November 12, 2026, 1.48 percent above the Xetra close of Wednesday, November 11, 2026 at EUR 26.27.
Funding Supports Obesity Drug Development
India Pharma Outlook reported on Thursday that Pfizer and Blackstone Life Sciences agreed on funding of up to USD 1.5 billion for the development of berobenatide. The agreement is intended to share part of the financial commitment for the program while Pfizer retains control of clinical development and commercialization.
Berobenatide is being developed as a monthly obesity treatment. The potential dosing schedule could support convenience if clinical trials establish safety and efficacy, but regulatory approval remains necessary before any commercial launch.
The funding adds financial support to Pfizer's obesity strategy, while the investment case still depends on clinical performance, tolerability and the program's progress through development. Pfizer's broader portfolio also includes medicines and vaccines across multiple therapeutic areas.
In the wider market, investors are also watching the S&P 500 for direction across major US equities.
More news and analyses on Pfizer stock are available on the company topic page.
